These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15291672)

  • 21. The functional anatomy, neurochemistry, and pharmacology of anxiety.
    Ninan PT
    J Clin Psychiatry; 1999; 60 Suppl 22():12-7. PubMed ID: 10634350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic benefits of serotonin and noradrenaline reuptake inhibition.
    Nelson JC
    Depress Anxiety; 1998; 7 Suppl 1():5-6. PubMed ID: 9597344
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
    Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
    Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
    J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venlafaxine: a 2003 update.
    Gutierrez MA; Stimmel GL; Aiso JY
    Clin Ther; 2003 Aug; 25(8):2138-54. PubMed ID: 14512125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.
    Montgomery SA; Sheehan DV; Meoni P; Haudiquet V; Hackett D
    J Psychiatr Res; 2002; 36(4):209-17. PubMed ID: 12191625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venlafaxine and SSRI remission data revisited.
    Kavirajan H
    Br J Psychiatry; 2004 May; 184():452-3. PubMed ID: 15123513
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of venlafaxine discontinuation symptoms with ondansetron.
    Raby WN
    J Clin Psychiatry; 1998 Nov; 59(11):621-2. PubMed ID: 9862610
    [No Abstract]   [Full Text] [Related]  

  • 30. Venlafaxine-associated hypomania in unipolar depression.
    Chand PK; Kalyani GS; Murthy P
    Can J Psychiatry; 2004 Jul; 49(7):496. PubMed ID: 15362257
    [No Abstract]   [Full Text] [Related]  

  • 31. Venlafaxine-induced hair loss.
    Pitchot W; Ansseau M
    Am J Psychiatry; 2001 Jul; 158(7):1159-60. PubMed ID: 11431245
    [No Abstract]   [Full Text] [Related]  

  • 32. Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine.
    Bertolín-Guillén JM; Climent-Díaz B; Navarré-Gimeno A
    Eur Psychiatry; 2004 Nov; 19(7):456-7. PubMed ID: 15504661
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug therapy in treatment-resistant depression.
    Malhi GS; Farmer AE
    Br J Psychiatry; 1999 Oct; 175():390-1. PubMed ID: 10789311
    [No Abstract]   [Full Text] [Related]  

  • 34. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mergers and acquisitions among psychotropics: antidepressant takeover of anxiety may now be complete.
    Stahl SM
    J Clin Psychiatry; 1999 May; 60(5):282-3. PubMed ID: 10362433
    [No Abstract]   [Full Text] [Related]  

  • 36. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
    Thase ME; Entsuah AR; Rudolph RL
    Br J Psychiatry; 2001 Mar; 178():234-41. PubMed ID: 11230034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Withdrawal syndrome after discontinuation of venlafaxine.
    Agelink MW; Zitzelsberger A; Klieser E
    Am J Psychiatry; 1997 Oct; 154(10):1473-4. PubMed ID: 9326838
    [No Abstract]   [Full Text] [Related]  

  • 38. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report.
    Bader GM; Hawley JM; Short DD
    J Clin Psychopharmacol; 1998 Jun; 18(3):255-6. PubMed ID: 9617988
    [No Abstract]   [Full Text] [Related]  

  • 39. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.
    Meoni P; Salinas E; Brault Y; Hackett D
    J Clin Psychiatry; 2001 Nov; 62(11):888-93. PubMed ID: 11775049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonin syndrome induced by administration of venlafaxine and phenelzine.
    Heisler MA; Guidry JR; Arnecke B
    Ann Pharmacother; 1996 Jan; 30(1):84. PubMed ID: 8773172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.